Salubris(SZ:002294) Xin Lang Cai Jing·2025-09-09 06:21Group 1 - The core point of the news is that Shenzhen Xinlitai Pharmaceutical Co., Ltd. experienced a stock decline of 5.01%, with a current share price of 55.53 yuan and a total market capitalization of 61.906 billion yuan [1] - The company was established on November 3, 1998, and went public on September 10, 2009. Its main business involves the research, production, and sales of pharmaceuticals and medical devices [1] - The revenue composition of the company is as follows: formulations account for 81.69%, medical devices 8.54%, raw materials 7.17%, and others 2.59% [1] Group 2 - From the perspective of fund holdings, one fund under GF Fund has a significant position in Xinlitai, specifically the GF Innovative Medicine ETF (515120), which held 1.8862 million shares, representing 2.64% of the fund's net value [2] - The GF Innovative Medicine ETF (515120) was established on December 3, 2020, with a current scale of 3.375 billion yuan. It has achieved a year-to-date return of 45.46% and a one-year return of 67.15% [2] - The fund manager, Luo Guoqing, has been in position for 9 years and 335 days, with the best fund return during his tenure being 70.24% and the worst being -48.08% [2]